Drug Profile


Latest Information Update: 16 Oct 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antiarrhythmics; Ischaemic heart disorder therapies
  • Mechanism of Action Alpha adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Angina pectoris; Arrhythmias; Heart failure; Hypertension

Most Recent Events

  • 16 Mar 1997 Discontinued - Phase-III for Angina pectoris in Germany (IV)
  • 16 Mar 1997 Discontinued - Phase-III for Arrhythmias in Germany (IV)
  • 16 Mar 1997 Discontinued - Phase-III for Heart failure in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top